TheEdgeResearch
Home / Stocks / IRME

IR-Med Inc. (IRME)

OTC Healthcare Medical - Devices
$0.00 ▲ +0.00%
Market Cap
$162,202
Sector
Healthcare
Industry
Medical - Devices
Beta
0.72
52-Wk Range
0.001-0.0527
CEO
Oded Bashan
Country
IL
Currency
USD

IR-Med Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Rosh Pinna, HZ, IL. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $162,202. On trailing twelve-month figures it carries a trailing P/E of -0.10, a net margin of 0.0%. Its beta of 0.72 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.10
Price / Sales
0.00
Price / Book
-0.25
EV / EBITDA
-0.66
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-0.40
Current ratio
0.12
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
3
IPO date
2021-01-26
Headquarters
Rosh Pinna, HZ, IL
About IR-Med Inc.

IR-Med Inc. is an emerging medical technology firm dedicated to developing advanced diagnostic and medical solutions by leveraging a platform that integrates infra-red light spectroscopy with artificial intelligence. The company's product pipeline includes PressureSafe, a handheld optical monitoring device engineered for the early identification of pressure-induced tissue damage in the skin and subcutaneous layers, often resulting from extended periods of patient immobility. Additionally, IR-Med is developing Nobiotics, an innovative otoscope designed to provide medical professionals with immediate feedback on the presence of middle ear infections (Otitis Media), a prevalent condition among pediatric patients. IR-Med Inc. operates from its headquarters in Rosh Pina, Israel.

Comparable companies

IR-Med Inc. is most often compared with the following Healthcare names:

LLBOLMLLFPLLWFRMSLRVVTFSIGYSLDXSTHZFTBRIFTLIS
More research on IRME
IRME technical analysis IRME TheEdge Score Compare against peers
Open full interactive analysis & DCF →